The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical ... (ing $876000 as compared to a loss fromdi...)

The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future

Date:10/30/2008

ing $876,000 as compared to a loss from discontinued operations of $445,000 for the same period in 2007.

The Company continues to invest in the development of natural-source potential products particularly for Diabetic Peripheral Neuropathy, the protection against infectious diseases in poultry products, disease states associated with inflammation, and protection against ionizing Radiation, as well as other health and wellness conditions.

Summary of major ethical pharmaceutical events that occurred during the third quarter of 2008:

Ongoing Quigley Pharma research and development initiatives include investing in its key pharmaceutical formulations, QR-333, an investigational new drug for treating conditions associated with Diabetic Peripheral Neuropathy. The Company is in the midst of a Phase II (b) clinical study for QR-333, which is a key segment of the Company's strategic initiatives to generate future growth.

During the third quarter of 2008, Quigley Pharma announced positive results of its study to determine the duration of the anti-viral effect of QR448(a), a veterinary anti-viral compound against Infectious Bronchitis Virus (IBV) in commercial broiler chickens, a consumer meat type bird. QR448(a) also prevented the transmission of IBV from infected to non-infected 2 week old commercial broiler chickens, a consumer meat type bird.

Veterinary poultry products industry experts and those familiar with prevention and control of IBV recognize that abating transmission is perhaps one of the most important ways to economically prevent, control and manage potential losses due to IBV outbreaks.

The Company plans to continue to build on these recent events to improve its potential commercial and partnering prospects.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow the aforementioned Investigational New Drug to be marketed. Furthermore, no cl
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
2. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
3. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
4. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
11. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19

Post Your Comments:

The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical ...(ing $876000 as compared to a loss fromdi...),Health